Chelsea Therapeutics (CHTP) craters in spite of announcing positive preliminary results for...
Tuesday, December 4, 2012, 5:04 PM ETChelsea Therapeutics (CHTP) craters in spite of announcing positive preliminary results for Study 306B, a Phase III trial of Northera, a treatment for hypotension associated with Parkinson's Disease, saying the trial met its primary endpoint. The devil lies in the details however, as investors react to the results under the shadow of the FDA's earlier statement that the trial was unlikely to provide sufficient confirmatory evidence to support an NDA. Shares -22% AH.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles